The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats

Basit Öğe Kaydı
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridKaradag, Cetin Hakan/0000-0002-4763-986X
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidKaradag, Cetin Hakan/H-4899-2013
dc.contributor.authorUlugol, A
dc.contributor.authorKaradag, HC
dc.contributor.authorIpci, Y
dc.contributor.authorTamer, M
dc.contributor.authorDokmeci, I
dc.date.accessioned2024-06-12T11:09:11Z
dc.date.available2024-06-12T11:09:11Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe antinociceptive action of cannabinoids in acute and inflammatory pain states have been well-documented. There is also accumulating evidence suggesting that cannabinoids are effective analgesics in chronic pain conditions. WIN 55,212-2, a mixed CB1 and CB2 cannabinoid receptor agonist, has been shown to be effective against hyperalgesia and allodynia in painful peripheral mononeuropathy. Recently, in addition to their spinal and supraspinal antinociceptive action, cannabinoids have also reported to exert local analgesic effects. The aim of this study is to observe the effect of a high affinity cannabinoid, WIN 55,212-2, on tactile allodynia and thermal hyperalgesia in diabetic rats. Diabetes was produced with the injection of a single dose of streptozocin (50 mg/kg, i.p.) and this procedure resulted in neuropathic pain behaviors in the hindlimbs. Mechanical allodynia was detected by application of von Frey filaments to the plantar surface of the foot, and thermal hyperalgesia was studied using the Hargreaves' method; however, thermal hyperalgesia did not develop in diabetic rats. With its higher doses, both systemic (3 and 10 mg/kg, i.p.) and peripheral (30 mug, i.p.l.) injections of WIN 55,212-2 reduced mechanical allodynia. These results suggest that WIN 55,212-2 has an antiallodynic effect in streptozocin-induced diabetic rats and may be a promising approach in the treatment of diabetic neuropathy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.neulet.2004.08.061
dc.identifier.endpage170en_US
dc.identifier.issn0304-3940
dc.identifier.issue2-3en_US
dc.identifier.pmid15519750en_US
dc.identifier.scopus2-s2.0-7444268551en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage167en_US
dc.identifier.urihttps://doi.org/10.1016/j.neulet.2004.08.061
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22704
dc.identifier.volume371en_US
dc.identifier.wosWOS:000225203800017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ireland Ltden_US
dc.relation.ispartofNeuroscience Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeuropathyen_US
dc.subjectPainen_US
dc.subjectAllodyniaen_US
dc.subjectWIN 55,212-2en_US
dc.subjectDiabetesen_US
dc.subjectCannabinoidsen_US
dc.subjectNeuropathic Painen_US
dc.subjectModelen_US
dc.subjectHyperalgesiaen_US
dc.subjectMorphineen_US
dc.subjectOpioidsen_US
dc.subjectAntinociceptionen_US
dc.subjectAmitriptylineen_US
dc.subjectStreptozocinen_US
dc.subjectReceptorsen_US
dc.titleThe effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu